Skip to content

Interest of the SPECT-CT Scan SUVspect in the New Generation of Gamma-cameras With Semiconductor

Quantification in Nuclear Medicine: Interest of the in SPECT-CT Scan SUVspect in Thea New Generation of Gamma-cameras With Semiconductor. Data Collection for the Constitution of an Observatory of Scintigraphies

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03414021
Acronym
GAMMA-CAM
Enrollment
250
Registered
2018-01-29
Start date
2018-01-31
Completion date
2025-12-30
Last updated
2024-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bone Diseases, Brain Diseases, Heart Diseases, Kidney Diseases, Thyroid Diseases

Keywords

Nuclear Medicine, SPECT-CT Scan, gamma-camera with semiconductor

Brief summary

Since 2017, a revolution began in the departments of nuclear medicine, with the routine use of gamma-cameras with semiconductor. These gamma-cameras (which obtained the CE-marking in 2016), offer a technological breakthrough by providing an additional information. They allow to quantify for the 1st time in clinical routine conditions, the quantity of radioactivity, by means of a SUVspect, in a volume of interest, while respecting the recommendations of best practice of the learned societies of French nuclear medicine (SFMN), European (EANM) and American (SNM), without injection of tracer nor acquisition or additional irradiation. The SUVspect is therefore an indicator of the quantity of tracer in a given volume of acquisition. Until now, the interpretation criteria of scintigraphies are based on the homogeneity of distribution of a tracer in the explored organ (for single organs such as the heart or the thyroid, for example) or in the asymmetry of distribution of the tracer (for the double organs, such as the kidney or the joints). This new gamma-camera allows to study the distribution of the radio-tracers in list mode, allowing to retrospectively reconstruct the images in various ways (for example, by modifying the size of the matrix of acquisition, the energy windows, the time of acquisition). Therefore, we can simulate and propose modifications in current procedures. Every patient referred to our department of nuclear medicine to undergo a scintigraphy with a tracer of nuclear medicine (with a marketing authorization) can, while benefiting from an examination by this gamma-camera, to be the object of this study, and to profit from this additional information. So, without changing the diagnosis or the usual care, we wish to take advantage of this additional information to improve the criteria of interpretation of our examinations. This possibility being new, there is no available bibliography (our department is the 5th department of nuclear medicine in Europe to equip itself with this large field-of-view gamma-camera CZT, the DNM 670, made by General Electric), while 2961 articles speak about the SUVmax (in PET) in Pubmed.

Interventions

DIAGNOSTIC_TESTSPECT-CT Scan

Injection of a Tracer and SPECT-CT Scan

Sponsors

Lille Catholic University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

\- informed adult patients referred to our department of nuclear medicine for a nuclear medicine exploration

Exclusion criteria

* Refusal to participate * Patient under guardianship

Design outcomes

Primary

MeasureTime frameDescription
SUVspect5 yearsPathological threshold (SUVspect) for every type of scintigraphy

Secondary

MeasureTime frameDescription
Matrix size5 yearsOptimize the reconstruction parameters of the images
duration of image acquisition5 yearsOptimize the reconstruction parameters of the images

Countries

France

Contacts

Primary ContactMarie Paule Lebitasy, MD
Lebitasy.Marie-Paule@ghicl.net03 20 22 57 41
Backup ContactWilliams VanDenBerghe
VanDenBerghe.Williams@ghicl.net03 20 22 57 31

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026